Bemnifosbuvir / Ruzasvir
Hepatitis C Virus (HCV)
Phase 3Active - Global Phase 3 program ongoing. Topline results expected 2026.
Key Facts
Indication
Hepatitis C Virus (HCV)
Phase
Phase 3
Status
Active - Global Phase 3 program ongoing. Topline results expected 2026.
Company
About Atea Pharmaceuticals
Atea Pharmaceuticals is a Boston-based, publicly traded biotech (Nasdaq: AVIR) focused on transforming the treatment of severe RNA viral infections with oral antivirals. The company's core strategy is built on its expertise in nucleos(t)ide chemistry and virology, targeting the viral RNA polymerase with a high barrier to resistance. Its most advanced asset is a pan-genotypic HCV regimen in Phase 3, with topline data expected in 2026, and it is expanding its pipeline to include other RNA viruses like hepatitis E. Atea's partnership with Roche for its COVID-19 candidate, AT-527, provides validation and potential commercial reach.
View full company profileTherapeutic Areas
Other Hepatitis C Virus (HCV) Drugs
| Drug | Company | Phase |
|---|---|---|
| Sofosbuvir + Velpatasvir (Hepcvir-V) | Natco Pharma | Approved |
| Ledipasvir + Sofosbuvir | Natco Pharma | Approved |